Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849313 | 0.85 | BCHE (0.48) | BRD4L3MBTL1MAPTCA1BCHE | |
| SCHEMBL2843448 | 0.84 | L3MBTL1 (0.46) | BRD4L3MBTL1MAPTRAB9ACA1 | |
| SCHEMBL372131 | 0.79 | PPARG (0.51) | L3MBTL1APOBEC3AAPOBEC3GMAPTPPARA | |
| SCHEMBL751290 | 0.78 | MAPT (0.60) | APOBEC3AAPOBEC3GMAPTPPARAPPARG | |
| SCHEMBL2838329 | 0.78 | BCHE (0.48) | BRD4L3MBTL1BCHEMEN1GAA | |
| SCHEMBL1717941 | 0.77 | MAPT (0.56) | MAPTPPARAPPARGRAB9ACA1 | |
| SCHEMBL5723717 | 0.76 | ALDH1A1 (0.53) | MAPTPPARAPPARGRAB9AGAA | |
| SCHEMBL5623908 | 0.76 | MAPT (0.59) | MAPTMEN1GAAHTTKMT2A | |
| SCHEMBL18664385 | 0.76 | HDAC1 (0.49) | L3MBTL1PPARAPPARGCA1CA2 | |
| SCHEMBL27262445 | 0.76 | PPARG (0.48) | L3MBTL1MAPTPPARAPPARGRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145879-B1 | Pyrazine derivatives, methods of use, and methods for preparing same | MEDIBEACON LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2145879-B1 | Pyrazine derivatives, methods of use, and methods for preparing same | MEDIBEACON LLC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8481734-B2 | Pyrazine derivatives and uses thereof, including in medical imaging and visualization applications | MEDIBEACON DEVELOPMENT LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100021382-A1 | Pyrazine Derivatives and Uses Thereof | MALLINCKRODT INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-2145879-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | DPYD, DHPS, DHX15 | BRD4 1173/4885L3MBTL1 4744/4885APOBEC3A 174/4885 |
| US-20100021382-A1 | Pyrazine Derivatives and Uses Thereof | DPYD, PRDX5, NOX5 | BRD4 463/4885L3MBTL1 4336/4885APOBEC3A 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.